KRAS and renal cell carcinoma: This contrasts with the genomic complexity and aggressive clinical behavior seen in KRAS-mutant PRCC and URCC, establishing PRNRP as a biologically and clinically distinct entity within the spectrum of KRAS-mutant RCC.